Raymond Pratt - Rockwell Medical Chief Medical Officer
| RMTI Stock | USD 1.53 0.01 0.66% |
Executive
Dr. Raymond Dennis Pratt, M.D. is a Chief Medical Officer of Rockwell Medical Inc. Prior to joining the Company, Dr. Pratt worked at Shire PLLC from 2003 to 2010 as vice president research and development and as the scientific leader in its Emerging Business Unit and Renal Business Unit. Previous roles at Shire included vice president global clinical medicine and global clinical affairs and head of US Clinical Development. Dr. Pratt served in a consulting role at Quintiles, a global biopharmaceutical services company, as a vice president of strategic drug development innovation from August 2011 until joining the Company, and as an industry consultant during 2011 after leaving Shire. Prior to working at Shire, he was senior director, clinical research and development at Eisai Medical Research from 1994 to 2003, where he was head of central nervous system and internal medicine clinical development. Dr. Pratt is a graduate of the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center where he practiced nephrology and served as the assistant chief of nephrology services and director of dialysis services from 1983 to 1985. Dr. Pratt was the recipient of a physician scientist training grant at Johns Hopkins School of Medicine and the recipient of a James Shannon New Investigator award from the NIH. He served as an assistant professor in the John Hopkins Department of Medicine and Nephrology from 1989 to 1993. since 2012.
| Age | 67 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Address | 30142 South Wixom road, Wixom, MI, United States, 48393 |
| Phone | 248 960 9009 |
| Web | https://www.rockwellmed.com |
Rockwell Medical Management Efficiency
The company has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4768) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.22. The current Return On Capital Employed is estimated to decrease to -0.2. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Craig MD | Alkermes Plc | 56 | |
| Raymond Vre | Dr Reddys Laboratories | 52 | |
| Eiry Roberts | Neurocrine Biosciences | 54 | |
| Malcolm LloydSmith | Neurocrine Biosciences | 62 | |
| Christopher Mutz | ANI Pharmaceuticals | 52 | |
| Kyle Gano | Neurocrine Biosciences | 51 | |
| Matthew MD | Deciphera Pharmaceuticals LLC | 68 | |
| Saunak Savla | Dr Reddys Laboratories | N/A | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | N/A | |
| RoseMarie Ohlsson | Alvotech Warrant | N/A | |
| Eva Gunnlaugsdottir | Alvotech Warrant | N/A | |
| Susan Mesco | Pacira Pharmaceuticals | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Jennifer PharmD | Avadel Pharmaceuticals PLC | N/A | |
| David Boyer | Neurocrine Biosciences | 44 | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
| Navjot Rai | Neurocrine Biosciences | ||
| Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
| Michael MD | Ironwood Pharmaceuticals | 64 | |
| Jason Vaughn | Avadel Pharmaceuticals PLC | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0844 |
Rockwell Medical Leadership Team
Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cooper, Director | ||
| David Domzalski, Director | ||
| Angus Smith, Principal Financial Officer | ||
| Thomas Klema, CFO, Vice President Treasurer, Secretary | ||
| Mark Strobeck, CEO President | ||
| Marc MD, Chief Officer | ||
| James McCarthy, Senior Development | ||
| Timothy Chole, Senior Marketing | ||
| Mark Ravich, Director | ||
| Michael DeYoung, Vice President - Operations | ||
| Kenneth Holt, Independent Director | ||
| Benjamin Wolin, Chairman of the Board | ||
| Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Megan Timmins, Chief VP | ||
| Patrick Bagley, Independent Director | ||
| David Kull, Principal Accounting Officer | ||
| Jim McCarthy, Senior Vice President - Corporate and Business Development | ||
| Jason Finkelstein, Investor Representative | ||
| Ajay Gupta, Chief Scientific Officer | ||
| Ronald Boyd, Independent Director | ||
| Lisa Colleran, Director | ||
| Jesse Neri, Senior Finance | ||
| Charlie Shiner, Vice President of Marketing | ||
| Raymond Pratt, Chief Medical Officer | ||
| Robin Smith, Director | ||
| Robert Chioini, Founder, Chairman of The Board and CEO | ||
| Heather Hunter, Senior Officer | ||
| Michael Rice, Co-Founder, LifeSci Advisors, LLC | ||
| Stuart Paul, CEO, Director |
Rockwell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0844 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 46.95 M | ||||
| Shares Outstanding | 29.36 M | ||||
| Shares Owned By Insiders | 3.00 % | ||||
| Shares Owned By Institutions | 16.69 % | ||||
| Number Of Shares Shorted | 675.7 K | ||||
| Price To Earning | (14.72) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rockwell Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rockwell Medical's short interest history, or implied volatility extrapolated from Rockwell Medical options trading.
Currently Active Assets on Macroaxis
When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Rockwell Stock analysis
When running Rockwell Medical's price analysis, check to measure Rockwell Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rockwell Medical is operating at the current time. Most of Rockwell Medical's value examination focuses on studying past and present price action to predict the probability of Rockwell Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rockwell Medical's price. Additionally, you may evaluate how the addition of Rockwell Medical to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Rockwell Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 3.585 | Quarterly Revenue Growth 0.144 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.